PA creates and develops its own IP. The latest example is Exacsys™, a PA venture company, which is helping improve the accuracy of self-monitoring of blood glucose (SMBG) systems for people with diabetes. Diabetes affects over 350 million people around the world and SMBG systems help them manage their condition.
The accuracy of current systems, however, has been called into question by patients as well as clinicians. Exacsys aims to substantially improve the self-monitoring of blood glucose, providing greater confidence in results and clinical management decisions.
Exacsys™ has demonstrated a 'proof of concept' system and is developing the technology further to take it to market.
To find out more about our groundbreaking product development, please contact us now.